SE

Senzime AB (publ)STO Senzime AB Stock Report

Last reporting period 30 Jun, 2024

Updated 04 Nov, 2024

Last price

Market cap $B

0.061

Micro

Exchange

XSTO - Nasdaq STOCKHOLM AB

SEZI.ST Stock Analysis

SE

Uncovered

Senzime AB (publ) is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-34/100

Low score

Market cap $B

0.061

Dividend yield

Shares outstanding

82.567 B

Senzime AB engages in the development of enzyme-based biosensor technology for medical and biochemical processes and industries. The company is headquartered in Uppsala, Uppsala. The company went IPO on 2008-06-18. The firm focuses on the following application areas: medical diagnostic instruments, pharmaceutical industry, chemical processing, and food and beverage processing. As of December 31, 2011, the Company marketed three products, namely SENZ-100G, for continuous analysis of glucose in the fermentation solutions; SENZ-100L, for continuous analysis of lactate in fermentation solutions, and SENZ-200G, for continuous analysis of glucose in blood during intensive care.

View Section: Eyestock Rating